| [1] |
王海燕,彭李博,王建军, 等. EphA1蛋白在卵巢浆液性腺癌中的表达及其临床意义[J]. 临床肿瘤学杂志, 2014, 19(11): 996-999.
|
| [2] |
李道胜,班媛媛. 卵巢伴微浸润的浆液性交界性肿瘤临床病理学特征分析[J/CD]. 中华诊断学电子杂志, 2016, 4(2): 116-119.
|
| [3] |
Liu M,Zhao S,Lin Q, et al.YAP regulates the expression of Hoxa1 and Hoxc13 in mouse and human oral and skin epithelial tissues[J]. Mol Cell Biol, 2015, 35(8): 1449-1461.
|
| [4] |
Greenspan DL,Connolly DC,Wu R, et al.Loss of FHIT expression in cervical carcinoma cell lines and primary tumors[J]. Cancer Res, 1997, 57(21): 4692-4698.
|
| [5] |
Dong J,Feldmann G,Huang J, et al.Elucidation of a universal size-control mechanism in drosophila and mammals[J]. Cell, 2007, 130(6): 1120－1133.
|
| [6] |
Lamar JM,Stern P,Liu H, et al.The hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain[J]. Proc Natl Acad Sci U S A, 2012, 109(37): E2441-2450.
|
| [7] |
Liu YC,Wang YZ.Role of Yes-associated protein 1 in gliomas：pathologic and therapeutic aspects[J]. Tumour Biol, 2015, 36(4): 2223-2227.
|
| [8] |
Cao JJ,Zhao XM,Wang DL, et al.YAP is overexpressed in clear cell renal cell carcinoma and its knockdown reduces cell proliferation and induces cell cycle arrest and apoptosis[J]. Oncol Rep, 2014, 32(4): 1594-1600.
|
| [9] |
Zhang L,Yang S,Chen X, et al.The hippo pathway effector, YAP, regulates motility, invasion and castration-resistant growth of prostate cancer cells[J]. Mol Cell Biol, 2015, 35(8): 1350-1362.
|
| [10] |
Guo J,Kleeff J,Zhao Y, et al. Yes-associated protein(YAP65) in relation to Smad7 expression in human pancreatic ductal adenocarcinoma[J]. Int J Mol Med, 2006, 17(5): 761-767.
|
| [11] |
Steinhardt AA,Gayyed MF,Klein AP, et al. Expression of Yes-associated protein in common solid tumors[J]. Hum Pathol, 2008, 39(11): 1582-1589.
|
| [12] |
Zhang X,George J,Deb S, et al. The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene[J]. Oncogene, 2011, 30(25): 2810-2822.
|
| [13] |
Muramatsu T,Imoto I,Matsui T, et al. YAP is a candidate oncogene for esophageal squamous cell carcinoma[J]. Carcinogenesis, 2011, 32(3): 389-398.
|
| [14] |
Muramatsu T,Imoto I,Matsui T, et al. YAP is a candidate oncogene for esophageal squamous cell carcinoma[J]. Carcinogenesis, 2011, 32(3): 389-398.
|
| [15] |
Kim JM,Kang DW,Long LZ, et al. Differential expression of Yes-associated protein is correlated with expression of cell cycle markers and pathologic TNM staging in non-small-cell lung carcinoma[J]. Hum Pathol, 2011, 42(3): 315-323.
|
| [16] |
Zhou Z,Zhu JS,Xu ZP.TRNA interference mediated YAP gene silencing inhibits invasion and metastasis of human gastric cancer cell line SGC-7901[J]. Hepatogastroenterology, 2011, 58(112): 2156-2161.
|
| [17] |
Tsujiura M,Mazack V,Sudol M, et al.Yes-associated protein (YAP) modulates oncogenic features and radiation sensitivity in endometrial cancer[J]. PLoS One, 2014, 9(6): e100974.
|
| [18] |
Hall CA,Wang R,Miao J, et al. Hippo pathway effector Yap is an ovarian cancer oncogene[J]. Cancer Res, 2010, 70(21): 8517-8525.
|
| [19] |
He C,Lv X,Hua G, et al.YAP forms autocrine loops with the ERBB pathway to regulate ovarian cancer initiation and progression[J]. Oncogene, 2015, 34(50): 6040-6054.
|
| [20] |
Yoshikawa K,Noguchi K,Nakano Y, et al. The Hippo pathway transcriptional co-activator, YAP, confers resistance to cisplatin in human oral squamous cell carcinoma[J]. Int J Oncol, 2015, 46(6): 2364-2370.
|